Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;5(1):91-2.
doi: 10.1177/1758834012464806.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

Maarten J Deenen  1 , Annemieke Cats, Jos H Beijnen, Jan H M Schellens
Affiliations

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

Maarten J Deenen et al. Ther Adv Med Oncol. 2013 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Cubero D., Cruz F., Santi P., Silva I., Del G. (2012) Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol 4: 167–172 - PMC - PubMed
    1. Deenen M., Cats A., Sechterberger M., Severens J., Smits P., Bakker R., et al. (2011) Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J Clin Oncol 29(Suppl. 15): 3606
    1. Deenen M., Terpstra W., Cats A., Boot H., Schellens J. (2010) Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 153: 767–768 - PubMed
    1. Ho D., Pazdur R., Covington W., Brown N., Huo Y., Lassere Y., et al. (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2’-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085–2088 - PubMed
    1. Kim W., Nakata B., Hirakawa K. (2007) Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 98: 1604–1608 - PMC - PubMed

LinkOut - more resources